Please login to the form below

Not currently logged in
Email:
Password:

Amicus

This page shows the latest Amicus news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs from Biogen and Amicus win UK Prix Galien

Orphan drugs from Biogen and Amicus win UK Prix Galien

New medical technology category added for the first time. Amicus’ Galafold and Biogen’s Spinraza have won the two top prizes at the UK Prix Galien, the biennial awards which recognise ... Amicus receive their award from health minister Lord

Latest news

More from news
Approximately 7 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    152. Calidus / Amicus. Acquisition. Purchase of Callidus' late-stage enzyme replacement therapy for Pompe disease.

  • Pharma deals during November 2013 Pharma deals during November 2013

    It was clearly a good news – bad news day for Amicus Therapeutics this month when two press releases were released. ... for Pompe disease. Amicus also announced plans to cut costs as part of a restructuring to focus on enzyme replacement therapies.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics